IL144727A0 - Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase - Google Patents
Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductaseInfo
- Publication number
- IL144727A0 IL144727A0 IL14472700A IL14472700A IL144727A0 IL 144727 A0 IL144727 A0 IL 144727A0 IL 14472700 A IL14472700 A IL 14472700A IL 14472700 A IL14472700 A IL 14472700A IL 144727 A0 IL144727 A0 IL 144727A0
- Authority
- IL
- Israel
- Prior art keywords
- components
- directed against
- antisense sequences
- ribonucleotide reductase
- sequences directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/249,730 US6121000A (en) | 1999-02-11 | 1999-02-11 | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
PCT/CA2000/000120 WO2000047733A1 (fr) | 1999-02-11 | 2000-02-09 | Sequences antisens antitumorales contre les constituants r1 et r2 de la ribonucleotide reductase |
Publications (1)
Publication Number | Publication Date |
---|---|
IL144727A0 true IL144727A0 (en) | 2002-06-30 |
Family
ID=22944744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14472700A IL144727A0 (en) | 1999-02-11 | 2000-02-09 | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase |
Country Status (17)
Country | Link |
---|---|
US (1) | US6121000A (fr) |
EP (1) | EP1153128B8 (fr) |
JP (1) | JP4424857B2 (fr) |
KR (1) | KR20020013501A (fr) |
CN (1) | CN1345373A (fr) |
AR (1) | AR022583A1 (fr) |
AT (1) | ATE309346T1 (fr) |
AU (1) | AU780455B2 (fr) |
BR (1) | BR0008788A (fr) |
CA (1) | CA2366487A1 (fr) |
DE (1) | DE60023845T2 (fr) |
ES (1) | ES2259602T3 (fr) |
IL (1) | IL144727A0 (fr) |
MX (1) | MXPA01008137A (fr) |
NZ (1) | NZ514090A (fr) |
RU (1) | RU2001124840A (fr) |
WO (1) | WO2000047733A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6593305B1 (en) * | 1996-08-02 | 2003-07-15 | Genesense Technologies Inc. | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
MXPA04010282A (es) * | 2002-04-18 | 2005-08-18 | Acuity Pharmaceuticals Inc | Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo. |
US7148342B2 (en) * | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
JP2006518344A (ja) * | 2003-02-10 | 2006-08-10 | ジェネセンス テクノロジーズ インク | リボヌクレオチド還元酵素r2を指向するアンチセンスオリゴヌクレオチドおよび癌の治療におけるこれらの使用 |
EP1615943A4 (fr) * | 2003-04-18 | 2006-08-16 | Univ Pennsylvania | Compositions et methodes d'inhibition par arnic de l'angiopoietine 1 et 2 et de leur recepteur tie2 |
CN1302936C (zh) * | 2003-05-02 | 2007-03-07 | 精工爱普生株式会社 | 打印机 |
EP1636363A1 (fr) * | 2003-05-21 | 2006-03-22 | GeneSense Technologies Inc. | Oligonucleotides antisens diriges contre le gene r1 de la ribonucleotide reductase et leurs utilisations dans le traitement du cancer |
WO2004106518A1 (fr) * | 2003-05-31 | 2004-12-09 | Genesense Technologies Inc. | Oligonucleotides antisens diriges contre la ribonucleotide reductase r2 et leurs utilisations dans le traitement du cancer |
CA2533701A1 (fr) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants |
WO2005065719A1 (fr) * | 2004-01-12 | 2005-07-21 | Genesense Technologies Inc. | Oligonucleotides antisens diriges contre la ribonucleotide reductase r2 et utilisation de ceux-ci dans des polytherapies destinees au traitement du cancer |
CA2564868C (fr) * | 2004-04-28 | 2013-11-26 | Molecules For Health, Inc. | Methodes permettant de traiter ou de prevenir la restenose et d'autres troubles vasculaires proliferants |
WO2006017932A1 (fr) * | 2004-08-18 | 2006-02-23 | Genesense Technologies Inc. | Molecules de petit arn interferant dirigees contre la ribonucleotide reductase et ses utilisations |
US20090130212A1 (en) * | 2006-05-15 | 2009-05-21 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
WO2007146953A2 (fr) * | 2006-06-12 | 2007-12-21 | Exegenics, Inc., D/B/A Opko Health, Inc. | COMPOSITIONS ET PROCÉDÉS DESTINÉS À UNE INHIBITION DE L'ANGIOGENÈSE PAR LES ARNsi |
US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
EP2030615A3 (fr) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Inhibiteurs de la ribonucleotide reductase pour leur utilisation dans le traitement ou la prévention de maladies neuro-inflammatoires ou auto-immunes |
US20100204305A1 (en) * | 2007-12-11 | 2010-08-12 | Lorus Therapeutics Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
CA2745832A1 (fr) | 2008-12-04 | 2010-06-10 | Opko Ophthalmics, Llc | Compositions et procedes pour l'inhibition selective d'isoformes pro-angiogeniques de vegf |
DE102019000490A1 (de) * | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5766855A (en) * | 1991-05-24 | 1998-06-16 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity and sequence specificity |
US5681747A (en) * | 1992-03-16 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof |
EP0690869A1 (fr) * | 1993-03-23 | 1996-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Regulation cellulaire a l'aide de riboregulateurs |
WO1998005769A2 (fr) * | 1996-08-02 | 1998-02-12 | Genesense Technologies, Inc. | Sequences antisens et antitumorales dirigees conte les constituants r1 et r2 de la ribonucleotide reductase |
-
1999
- 1999-02-11 US US09/249,730 patent/US6121000A/en not_active Expired - Fee Related
-
2000
- 2000-02-09 WO PCT/CA2000/000120 patent/WO2000047733A1/fr active IP Right Grant
- 2000-02-09 ES ES00903456T patent/ES2259602T3/es not_active Expired - Lifetime
- 2000-02-09 MX MXPA01008137A patent/MXPA01008137A/es not_active Application Discontinuation
- 2000-02-09 NZ NZ514090A patent/NZ514090A/en not_active IP Right Cessation
- 2000-02-09 RU RU2001124840/15A patent/RU2001124840A/ru unknown
- 2000-02-09 KR KR1020017010204A patent/KR20020013501A/ko not_active Application Discontinuation
- 2000-02-09 EP EP00903456A patent/EP1153128B8/fr not_active Expired - Lifetime
- 2000-02-09 JP JP2000598631A patent/JP4424857B2/ja not_active Expired - Fee Related
- 2000-02-09 IL IL14472700A patent/IL144727A0/xx unknown
- 2000-02-09 CN CN00805667A patent/CN1345373A/zh active Pending
- 2000-02-09 AU AU25292/00A patent/AU780455B2/en not_active Ceased
- 2000-02-09 BR BR0008788-2A patent/BR0008788A/pt not_active Application Discontinuation
- 2000-02-09 CA CA002366487A patent/CA2366487A1/fr not_active Abandoned
- 2000-02-09 AT AT00903456T patent/ATE309346T1/de not_active IP Right Cessation
- 2000-02-09 DE DE60023845T patent/DE60023845T2/de not_active Expired - Lifetime
- 2000-02-11 AR ARP000100613A patent/AR022583A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2000047733A1 (fr) | 2000-08-17 |
EP1153128B1 (fr) | 2005-11-09 |
RU2001124840A (ru) | 2004-03-27 |
DE60023845D1 (de) | 2005-12-15 |
EP1153128A1 (fr) | 2001-11-14 |
KR20020013501A (ko) | 2002-02-20 |
ATE309346T1 (de) | 2005-11-15 |
AR022583A1 (es) | 2002-09-04 |
AU780455B2 (en) | 2005-03-24 |
DE60023845T2 (de) | 2006-08-10 |
JP4424857B2 (ja) | 2010-03-03 |
CA2366487A1 (fr) | 2000-08-17 |
BR0008788A (pt) | 2001-11-06 |
AU2529200A (en) | 2000-08-29 |
EP1153128B8 (fr) | 2006-01-18 |
WO2000047733A9 (fr) | 2001-03-15 |
JP2003500006A (ja) | 2003-01-07 |
ES2259602T3 (es) | 2006-10-16 |
US6121000A (en) | 2000-09-19 |
CN1345373A (zh) | 2002-04-17 |
NZ514090A (en) | 2005-01-28 |
MXPA01008137A (es) | 2004-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL144727A0 (en) | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase | |
EP0984161A4 (fr) | Combinaison de cale et de came | |
EP1090025A4 (fr) | Modulation antisens de l'expression du tnfr1 | |
AU6296199A (en) | Antisense modulation of smad1 expression | |
GB9807200D0 (en) | Item of underwear | |
EP1009860A4 (fr) | Inhibition du gene ras a l'aide d'oligonucleotides antisens | |
AU2002365920A8 (en) | Antisense modulation of complement component c3 expression | |
EP1206478A4 (fr) | Composes antisens modulant l'expression de mekk5 | |
HK1042392A1 (en) | Transceiver and method of receiving signals | |
IL136156A0 (en) | Sequences of trail variants | |
AU2002366788A8 (en) | Antisense modulation of ship-1 expression | |
PL347119A1 (en) | Method of obtaining peroxysulphates of alkali metals and ammonium | |
EP1197122A4 (fr) | Ecouteur sans impulsion et sans bruit haute frequence | |
PL336286A1 (en) | Rear handrail and method of mounting same | |
GB9612442D0 (en) | Biodegradation of metal cyanides | |
HK1048405A1 (en) | Synchronizing pcm and pseudorandom clocks | |
PL339493A1 (en) | Bis-ethers of 1-oxa, aza and thinaphtalen-2-ones as phospholamane inhibitors | |
AU6920898A (en) | Antisense inhibition of human stat-6 | |
GB9819137D0 (en) | Component of bromelain | |
GB0201026D0 (en) | Body part substitute and method of mounting the same | |
AU2845300A (en) | Antisense modulation of smad5 expression | |
AU2002353026A8 (en) | Antisense modulation of nod1 expression | |
GB9918880D0 (en) | An article of clothing | |
GB2363981B (en) | Assemblies of Case-holder and Case | |
GB2331343B (en) | Fixings and methods of assembly |